Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 6/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | AXL | P30530 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16751174 | 0.93 | NOS1 (0.53) | NOS1MAPTCYP3A4LMNAALOX15 | |
| SCHEMBL11680975 | 0.86 | MAPT (0.59) | NOS1MAPTCYP3A4LMNAALOX15 | |
| SCHEMBL27228526 | 0.80 | NOS1 (0.53) | NOS1MAPTCYP3A4LMNAALOX15 | |
| SCHEMBL31717179 | 0.80 | NOS1 (0.53) | NOS1MAPTCYP3A4LMNAALOX15 | |
| SCHEMBL28629877 | 0.80 | NOS1 (0.53) | NOS1MAPTCYP3A4LMNAALOX15 | |
| SCHEMBL28067945 | 0.80 | NOS1 (0.53) | NOS1MAPTCYP3A4LMNAALOX15 | |
| SCHEMBL1024276 | 0.80 | NOS1 (0.53) | NOS1MAPTCYP3A4LMNAALOX15 | |
| SCHEMBL17373905 | 0.80 | NOS1 (0.53) | NOS1MAPTCYP3A4LMNAALOX15 | |
| SCHEMBL1026662 | 0.78 | NOS1 (0.54) | NOS1MAPTCYP3A4LMNAALOX15 | |
| SCHEMBL29680531 | 0.78 | NOS1 (0.54) | NOS1MAPTCYP3A4LMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098028-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-04-09 | — | — | US | disclosed |
| US-12441711-B2 | Compounds and their use for treatment of hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-10-14 | — | — | US | disclosed |
| US-12404274-B2 | Macrocycles as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| CN-120129677-A | Compounds and their use for the treatment of heme lesions | 百时美施贵宝公司 | 2025-06-10 | — | — | CN | disclosed |
| US-20250163025-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250032476-A1 | ALPHA-2A ADRENERGIC RECEPTOR MODULATORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2025-01-30 | — | — | US | disclosed |
| WO-2024188246-A9 | NITROGEN-CONTAINING MACROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海宇道生物技术有限公司 | 2024-12-05 | — | — | WO | disclosed |
| WO-2024188246-A1 | NITROGEN-CONTAINING MACROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海宇道生物技术有限公司 | 2024-09-19 | — | — | WO | disclosed |
| EP-4426287-A1 | ALPHA-2A ADRENERGIC RECEPTOR MODULATORS AND USES THEREOF | The Regents of the University of California (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20240208937-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2014179154-A2 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-11-06 | — | — | WO | disclosed |
| EP-2563358-A1 | INHIBITORS OF PHOSPHOINOSITIDE DEPENDENT KINASE 1 (PDK1) | Merck Sharp & Dohme Corp. (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20130053382-A1 | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) | PALIWAL SUNIL (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053382-A1 | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) | PALIWAL SUNIL (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053382-A1 | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) | PALIWAL SUNIL (US) | 2013-02-28 | — | — | US | disclosed |
| EP-2534154-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120041190-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-16 | — | — | US | disclosed |
| WO-2011137219-A1 | INHIBITORS OF PHOSPHOINOSITIDE DEPENDENT KINASE 1 (PDK1) | SCHERING CORPORATION (US) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011100401-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20050113370-A1 | Therapeutic substituted indazole derivatives | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041190-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | NOS1 3314/4885MAPT 326/4885CYP3A4 1109/4885 |
| US-12404274-B2 | Macrocycles as factor xia inhibitors | TFPI, TFPI2, F11 | NOS1 3314/4885MAPT 326/4885CYP3A4 1109/4885 |
| US-20130053382-A1 | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) | PDK1, PDPK1, PDK3 | NOS1 3945/4885MAPT 3602/4885CYP3A4 4420/4885 |
| US-20240208937-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | HBG1, HBG2, HBB | NOS1 2512/4885MAPT 4138/4885CYP3A4 1514/4885 |
| US-20250163025-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | HBG1, HBG2, HBB | NOS1 2512/4885MAPT 4138/4885CYP3A4 1514/4885 |
| US-20050113370-A1 | Therapeutic substituted indazole derivatives | NR4A3, CBR3, NR3C2 | NOS1 236/4885MAPT 2429/4885CYP3A4 83/4885 |
| US-20250032476-A1 | ALPHA-2A ADRENERGIC RECEPTOR MODULATORS AND USES THEREOF | ADRA2A, ADRB2, ADRA2C | NOS1 3156/4885MAPT 4117/4885CYP3A4 1027/4885 |
| US-12441711-B2 | Compounds and their use for treatment of hemoglobinopathies | HBG1, HBG2, HBB | NOS1 2512/4885MAPT 4138/4885CYP3A4 1514/4885 |
| US-20260098028-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | HBZ, HBG2, HBB | NOS1 1255/4885MAPT 3444/4885CYP3A4 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.